Aberdeen Group plc Buys 436,673 Shares of Shattuck Labs, Inc. $STTK

Key Points

• Aberdeen Group plc boosted its stake in Shattuck Labs by 462.1% in Q4, buying 436,673 shares to hold 531,177 shares (about 0.84% ownership) valued at $1.939 million.
• Analyst sentiment is broadly positive with a consensus rating of "Moderate Buy" and a consensus target price of $10.50 (6 Buys, 1 Hold, 1 Sell), with price targets ranging from $7 to $25 from various firms.
• Shares opened at $7.40 (12‑month range $0.71–$7.68) with a market cap of roughly $529.5M; latest quarter showed EPS of ($0.12) (in line with estimates) and revenue of ($1.0)M versus expected $0.17M.

Aberdeen Group plc increased its stake in Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) by 462.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 531,177 shares of the company's stock after purchasing an additional 436,673 shares during the period. Aberdeen Group plc owned approximately 0.84% of Shattuck Labs worth $1,939,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC bought a new position in Shattuck Labs in the third quarter valued at about $29,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs during the third quarter worth about $38,000. Squarepoint Ops LLC bought a new stake in shares of Shattuck Labs during the third quarter worth about $46,000. Mallini Complete Financial Planning LLC bought a new stake in shares of Shattuck Labs during the fourth quarter worth about $83,000. Finally, AQR Capital Management LLC grew its holdings in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after purchasing an additional 31,355 shares during the last quarter. Institutional investors own 58.74% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Citigroup lifted their price objective on Shattuck Labs from $4.00 to $7.00 and gave the stock a "neutral" rating in a research note on Friday, March 13th. Piper Sandler assumed coverage on Shattuck Labs in a research note on Wednesday, January 28th. They issued an "overweight" rating and a $15.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Needham & Company LLC started coverage on Shattuck Labs in a research note on Friday, March 6th. They issued a "buy" rating and a $25.00 price objective on the stock. Finally, Wall Street Zen raised Shattuck Labs from a "hold" rating to a "buy" rating in a research note on Saturday, March 28th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Shattuck Labs presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.50.

Shattuck Labs Stock Up 5.4%

Shares of NASDAQ:STTK opened at $7.40 on Friday. Shattuck Labs, Inc. has a twelve month low of $0.71 and a twelve month high of $7.68. The stock's 50 day moving average is $5.16 and its 200-day moving average is $3.63. The firm has a market capitalization of $529.54 million, a price-to-earnings ratio of -9.61 and a beta of 1.28.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). The firm had revenue of ($1.00) million for the quarter, compared to analyst estimates of $0.17 million. Equities research analysts anticipate that Shattuck Labs, Inc. will post -1.48 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc NASDAQ: STTK is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.